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Abstract
Background: New-onset diabetes mellitus after transplantation (NODAT), a frequent and serious complication after
transplantation, is associated with decreased graft and patient survival. Currently, it is diagnosed and treated
primarily according to existing guidelines for type II diabetes. To date, only a few trials have studied antidiabetic
drugs in patients with NODAT. Vildagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that improves
pancreatic islet function by enhancing both a- and b-cell responsiveness to increased blood glucose. Experimental
data show potential protective effects of DPP-4 inhibitors on islet function after exogenous stress stimuli including
immunosuppressants. Therefore, the therapy of NODAT with this class of compounds seems attractive. At present,
vildagliptin is used to treat type II diabetes as monotherapy or in combination with other antidiabetic drugs, since
that it efficiently decreases glycated hemoglobin (HbA1c) values. Additionally, vildagliptin has been shown to be
safe in patients with moderately impaired kidney function. This study will evaluate the safety and efficacy of
vildagliptin monotherapy in renal transplant recipients with recently diagnosed NODAT.
Methods/Design: This study is a randomized, placebo-controlled, double-blind, prospective phase II trial. Using the
results of routinely performed oral glucose tolerance tests (OGTT) in stable renal transplant patients at our center,
we will recruit patients without a history of diabetes and a 2 h glucose value surpassing 200 mg/dl (11.1 mmol/l).
They are randomized to receive either 50 mg vildagliptin or placebo once daily. A total of 32 patients with newly
diagnosed NODAT will be included. The primary endpoint is the difference in the 2 h glucose value between
baseline and the repeated OGTT performed 3 months after treatment start, compared between the vildagliptin-
and the placebo-group. Secondary endpoints include changes in HbA1c and fasting plasma glucose (FPG). The
safety of vildagliptin in renal transplant patients will be assessed by the number of symptomatic hypoglycemic
episodes (glucose <72 mg/dl or 4 mmol/l), the number of adverse events, and possible medication-associated
side-effects.
Discussion: NODAT is a severe complication after kidney transplantation. Few trials have assessed the safety and
efficacy of antidiabetic drugs for these patients. The purpose of this study is to assess the safety and efficacy of
vildagliptin in renal transplant patients with NODAT.
Trial Registration: ClinicalTrials.gov NCT00980356.
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New-onset diabetes after transplantation (NODAT), also
called post-transplant diabetes mellitus (PTDM),
remains a severe metabolic complication in patients
after organ transplantation. NODAT leads to an
increased incidence of cardiovascular disease (CVD) and
consequently reduced graft and patient survival [1,2]. In
non-transplanted patients, diabetes mellitus (DM) has
been identified as a major independent risk factor for
CVD [3]. CVD includes atherosclerotic coronary heart
disease, heart failure, myocardial infarction, stroke and
peripheral vascular disease [4]. Patients with CVD and
DM suffer from a worse prognosis for survival than
patients without these conditions. In organ transplant
recipients, mortality due to CVD remains the most com-
mon cause of mortality [1]. In renal transplant recipients
NODAT is associated not only with increased cardiovas-
cular morbidity and mortality, but also with impaired
long-term graft function and increased risk of graft loss
[4,5]. Hence, NODAT needs medical attention and
treatment and therefore clinical trials with antidiabetic
drugs for the therapy of NODAT remain of high
interest.
The reported incidence of NODAT varies between 2
and 53%. This high variability is due the lack of a stan-
dard definition in clinical studies [6]. Some reports
define NODAT by the requirement for exogenous insu-
lin without further examinations, such as an oral glucose
tolerance test (OGTT). Currently, the diagnosis of
NODAT is based on guidelines for type II diabetes
(T2DM) from the American Diabetes Association
(ADA), which include impaired glucose tolerance (IGT)
and impaired fasting glucose (IFG) as diagnostic para-
meters [7]. Development of NODAT has modifiable (e.
g. body weight, immunosuppressive drug therapy) and
non-modifiable (e.g. age, ethnicity, polycystic kidney dis-
ease) risk factors [8]. The role of immunosuppressants
(e.g. corticosteroids or calcineurin inhibitors (CNIs)) in
the clinical course of diabetes is clearly established, and
disease development is probably mediated by an
increased beta-cell apoptosis and impaired insulin sensi-
tivity [4,9]. The incidence of steroid-induced diabetes is
related to the treatment duration and the dose of corti-
costeroids [10]. Some authors propose steroid reduction
or complete withdrawal as a means to reduce the inci-
dence of NODAT, but steroid withdraw has been asso-
ciated with an increased risk for graft rejection [4].
Most centers currently follow so-called “step-up” stra-
tegies established for the treatment of T2DM starting
with non-pharmacological therapies and life-style modi-
fication, subsequently followed by oral antidiabetic ther-
apy and finally insulin [4]. Pharmacodynamic and
pharmacokinetic drug properties may be altered in
patients with renal impairment and new drugs have to
be studied regarding safety and effectiveness in patients
with impaired renal function. In renal transplant
patients, drugs are at additional risk of interacting with
i m m u n o s u p p r e s s i v ea g e n t sa sw e l la sw i t ho t h e rc o -
medications [11].
Vildagliptin, a dipeptidyl peptidase IV (DPP-4) inhibi-
tor that, belongs to a new class of oral antidiabetic
d r u g s[ 1 2 ] .D P P - 4i n h i b i t o r se n h a n c et h ea c t i v i t yo f
incretin hormones in response to a glucose load by
blocking the hormones responsible for incretin degrada-
tion [13]. Incretins are gut hormones that are secreted
from enteroendocrine cells into the blood within
minutes after food intake. The incretin hormones
glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) have been reported to
exert numerous metabolic effects contributing to the
regulation of blood glucose levels [14]. Vildagliptin
decreases glycated hemoglobin (HbA1c) in patients with
T2DM when given as monotherapy or combined with
metformin or glitazones [15-19]. Furthermore, vildaglip-
t i nh a sb e e ns h o w nt ob es a f ei np a t i e n t sw i t hm i l dt o
moderately impaired kidney function [20].
This study aims to assess the safety and efficacy of vil-
dagliptin in patients with NODAT.
Methods/Design
Hypothesis
Vildagliptin improves glucose metabolism in patients
suffering from newly diagnosed NODAT.
Objectives
This 16-week trial aims to evaluate the safety and effi-
cacy of vildagliptin in stable renal transplant recipients
with newly diagnosed NODAT.
The primary outcome parameter will be the difference
in 2 h glucose levels obtained during an OGTT between
stable renal transplant patients receiving vildagliptin or
placebo after 3 months treatment.
The secondary study outcomes will include change in
HbA1c and fasting plasma glucose after three months of
treatment, the safety of vildagliptin in renal transplant
recipients regarding kidney function, liver function and
the potential for drug-drug interactions with immuno-
suppressive medications (Intention to treat (ITT) analy-
sis), the safety of vildagliptin for glycemic control in
patients with impaired kidney function, and the long-
lasting effects of vildagliptin on b-cell function one
month after treatment stop.
Study design and setting
This study is a prospective, single-center, double-blind,
randomized, placebo-controlled, phase II trial in patients
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follow-up are conducted at the Medical University of
Vienna. The study recruitment has started in February
2010.
Study setting
Patients with a stable kidney allograft, more than 6
months after transplantation, without a history of
T1DM or T2DM routinely undergo an OGTT at our
outpatient department. All patients with a pathological
OGTT (serum glucose levels ≥ 200 mg/d (11.1 mmol/
L)) are classified as patients suffering from NODAT. 32
Patients eligible for the study are invited to the outpati-
ent clinic and therapeutic options are discussed. Patients
who are willing to take part in the study and have
signed their informed consent form are randomized in a
1:1 ratio into study arm A (vildagliptin) or study arm B
(placebo). The detailed study flow chart and an overview
of study procedures are depicted in Figure 1 and 2,
respectively.
Study intervention
Patients will receive their study medication (vildagliptin
or placebo) with instructions to take it once daily 30
minutes before breakfast. Patients will receive continu-
ous counseling on lifestyle modification (e.g. diet, physi-
cal exercise) until the end of the study. Participants in
t h es t u d yh a v et ob eo nat r i p l ei m m u n o s u p p r e s s i v e
therapy consisting of a CNI (tacrolimus or cyclosporine
A), prednisolone, and mycophenolic acid, either as the
prodrug (mycophenolate mofetil) or as delayed-release
mycophenolic sodium. All changes in concomitant med-
ication will be recorded. Patients will have a visit at our
outpatient clinic during weeks 2, 4, 8, 12, and 16 (Fig-
ure 2). At each visit, blood samples are collected to
determine blood parameters including complete blood
count, serum chemistry, C-reactive protein, creatinine,
calculated glomerular filtration rate (cGFR) using the
“Modification of Diet in Renal Disease” (MDRD) for-
mula, potassium, sodium, phosphate, chloride, calcium,
total bilirubin, ALAT, ASAT, total protein, LDL, HDL,
triglycerides. Patients with a cGFR between 30 and 50
mL/min./1.73 m
2 will have weekly blood checks com-
prising creatinine and ASAT/ALAT during the first
month for safety reasons. Each patient is expected to
parcipate in the study for 120 days. Unblinding of the
s t u d yw i l lb ep e r f o r m e da f t e rt h ee n do ft h ec o m p l e t e
trial. Patients whose OGTT did not improve 4 months
after study start will be treated by the physicians of our
outpatient clinic according to the guidelines.
Informed consent
The investigator explains the nature of the study, its
purpose, procedures, expected duration, and the poten-
tial risks and benefits associated with study participation
along with any discomfort that may be expected.
Patients will be informed about the strict confidentiality
of their subject data, but also that their medical records
may be reviewed for trial purposes by authorized indivi-
duals other than their treating physician. Each subject
will be informed that study participation is voluntary
and withdrawal is possible at any time during the study
period. Withdrawal will not prejudice the subject’ss u b -
sequent care. Subjects are given time to read and under-
stand the statements before signing consent and dating
the document. Subjects receive a copy of the signed
written statement and the original copy of the informed
consent is stored in the investigator study files. No sub-
ject is entered into the study until informed consent has
been obtained.
Safety assessments
Safety assessments will include the monitoring and
recording of all adverse events (AE), including serious
adverse events (SAE). An AE is any undesirable experi-
ence associated with the use of a medical product in a
patient. An SAE is defined as any untoward medical
occurrence that at any dose results in death, is life-
threatening, requires inpatient hospitalization or prolon-
gation of existing hospitalization, or results in persistent
or significant disability/incapacity. The most probable
AEs caused by vildagliptin are consistent with the
known side-effects, which are the cause of the previously
described exclusion criteria (table 1), such as wound
healing disorders or severe renal impairment. The
Figure 1 Flowchart of the Study.
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drugs might be triggered by AE, diagnostic or therapeu-
tic procedures, abnormal laboratory values (e.g. basal
ASAT/ALAT 50% elevated or more, serum creatinine
25% elevated or more) and for administrative reasons, in
particular the withdrawal of the patient’s consent.
Statistical analysis plan
The statistical analysis plan (SAP) provides full details
regarding the analyses, the data display, and the algo-
rithms to be used for data derivations. The SAP includes
the definition of major and minor protocol deviations
which will be identified by medically trained staff before
the study closure. Safety and tolerability are analyzed
descriptively. Safety analysis is performed on the ITT
population.
The study sample will consist of 32 patients with
newly diagnosed NODAT. For the primary endpoint
analysis, we will assess the differences between treat-
ment and control group in the 2 h glucose value
obtained during an OGTT (75 g glucose) after 3 months
of vildagliptin or placebo treatment. Based on a two-
sided testing and a standard deviation of 20% in relative
changes of 2 h OGTT glucose values, a =0 . 0 5a n dß=
0.2, a sample size of 16 patients per group can detect a
minimal difference in serum glucose level of 20 mg/dl at
the 2 hour time point of the OGTT when comparing
baseline levels to levels on day 90. The “Last observation
carried forward” (LOCF) method will be used for miss-
ing data.
Two different analysis sets are defined for safety and
efficacy, respectively. The efficacy of vildagliptin is
assessed in all subjects who received the study drug (at
least one dose) and did not violate the protocol in a way
that might affect the evaluation of the effect of the
study drug(s) on the primary objective, i.e. without
major protocol violations. The per-protocol set is
employed in the analysis of efficacy variables. A sensitiv-
ity analysis will be performed for efficacy with the ITT
population.
The safety analysis set includes subjects who were ran-
domized and received at least one dose of the study
drug (modified intention to treat). The safety set is
employed in the analysis of tolerability and safety vari-
ables. Statistical analysis is performed with SPSS.
Approval of the ethics committee and the regulatory
authority
The trial is performed in accordance with the Declara-
tion of Helsinki as well as the Austrian drug law. It sub-
scribes to the principles outlined in the most recent
version of the International Conference on Harmoniza-
tion on Good Clinical. Approvals were obtained from
the ethics committee of the Medical University of
Vienna and the Vienna General Hospital (Reference
Number 645/2009) and from the Austrian regulatory
authority (Federal Office for Safety in Health Care, Aus-
trian Agency for Health and Food Safety) and was regis-
tered to the European Clinical Trials Database
(EUDRACT number: 2009-14405-14). The study has
also been registered in a public clinical trial database
(Identifier Number NCT00980356, http://clinicaltrial.
gov).
Discussion
Risk-benefit assessment
We expect all patients participating in this study to ben-
efit because of patient counseling and emphasis placed
on life-style modification in both study arms. Counsel-
ing is performed according to the guidelines of the
Figure 2 Study procedures. OGTT, oral glucose tolerance test.
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hypothesis is true, the vildagliptin group (study arm A)
will experience improved glycemic control. Vildagliptin
is well tolerated in patients with mild to moderate renal
impairment [20]. Patients with severe renal impairment
(GFR < 30 mL/min/1.73 m
2) will not be included in our
study. Patients with a GFR between 30 and 50 mL/min./
1.73 m
2 will have weekly visits at our outpatient clinic
during the first 4 weeks (serum-creatinine and ASAT/
ALAT) for safety. If renal function declines for any rea-
son to a level below 30 mL/min/1.73 m
2, administration
of the study medication will be stopped.
NODAT continues to be a common and serious meta-
bolic complication after organ transplantation. Cur-
rently, NODAT is diagnosed and treated like T2DM,
but there is only limited evidence about the efficacy and
safety of the novel antidiabetic drug vildagliptin in
patients with NODAT, although it is already commonly
used in T2DM. Based on the differences in pathophy-
siology between T2DM and NODAT, the complex drug
profiles in transplanted patients, and the possible influ-
ence of renal impairment on the pharmacokinetic prop-
erties of vildagliptin, the antidiabetic efficiency of this
drug in NODAT remains to be established. This trial
will investigate whether vildagliptin is efficient and safe
in patients with NODAT.
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